• Sarah Howell, Ph.D., Chief Executive Officer

    Sarah, who joined Arecor in 2013, before being appointed Chief Executive Officer to the Group in 2015, has a strong background in clinical and commercial pharmaceutical product development, manufacture, supply and licensing across a range of product types and therapeutic areas. She has served in a number of leading roles in the pharmaceutical industry, most recently as Vice President for CMC (Chemistry, Manufacturing & Controls) and Technical Development for BTG where she had full responsibility for CMC development and supply across BTG’s diverse portfolio of clinical and commercial products.

    Previously she held senior roles in product development and manufacturing for UCB-Celltech and GlaxoSmithKline. She is also an active member of the BioIndustry Association (BIA) Manufacturing Advisory Committee.

    Sarah has an honours degree in Chemistry from the University of Birmingham and a Ph.D. in Physical Organic Chemistry from the University of St Andrews.

  • Jan Jezek, Ph.D., Chief Scientific Officer

    Jan is a biochemist with a strong background in physical chemistry and the principal inventor of the core protein stabilisation technologies. Currently he is responsible at Arecor for R&D activities, platform development and IP strategy. He played a critical role in the development of stabilising technologies for commercially important therapeutic proteins and vaccines that form the core of Arecor business.

    Previously, he was a Principal Scientist at Insense Limited, a spin-out from Unilever, where he was responsible for the development of novel medical devices, taking them from concept to market.

    Jan holds a joint Doctorate from the University of Bedfordshire and the University of Chemical Technology, Prague. He is a member of the Scientific Advisory Board of the Centre of Excellence in Biopharmaceuticals (University of Manchester) and is an active member of the Formulation Science & Technology Group (FSTG) at the Royal Society of Chemistry and the Biopharmaceutical Group at the Academy of Pharmaceutical Sciences (APS).

  • David Gerring, Director of Development

    David has 15 years’ experience in pharmaceutical product and analytical development, as well as significant regulatory and quality experience. He has held senior roles at Immunocore and Emergent BioSolutions and his experience includes 5 years at UCB, whilst in a scientific and regulatory capacity. There, he focused on the development and successful licensure of Cimzia. He headed up process and analytical development at BTG, managing CMC for several recombinant products, including successful INDs and licensures.

    He is currently Director of Development and operations at Arecor, with a wide range of responsibilities, including: scientific strategy, project management, facilities, health & safety, quality and client procurement, grant and internal product development management.

  • Fiona Lawrence, Director of Project Management

    Fiona is a pharmaceutical research and development professional and is currently Director of Project Management at Arecor, where she has responsibility for driving the clinical development of Arecor’s proprietary products’ portfolio.

    She has broad expertise and experience stemming from work across different organisations in the biotech/pharma, public and not-for-profit/charitable sectors. Previously, she was Director of Research and Clinical Development at Duchenne UK with responsibility for developing the research strategy for the charity. She spent five years at BioMarin and Prosensa in Leiden, working as Senior Clinical Research Manager and four years as Commercial Trials Manager at Cambridge University Hospitals.

    Fiona holds an MSc in Pharmaceutical Medicine from the University of Surrey and a BSc in Pharmacology from the University of Bath.

  • Laura Ciccolini, Ph.D., Director of Business Development & Licensing

    Laura joined Arecor in 2018 as Director of Business Development. Coming from a background in Engineering, she has gained international experience across a number of business functions in the pharmaceutical, biotechnology and engineering/technology industries. She is multi-lingual and has built and trained successful teams, developed products and services, and managed complex programmes on a global scale, enabling expansion of businesses across markets.

    Her most recent experience includes acting as Commercial Director at Bedrock Healthcare Communications Ltd, to provide medical communications, education and strategic counsel to the pharma and biopharma industries. Prior to that, she was Commercial Director and Member of the Executive Board at Biopharma Technology Limited, part of the Biopharma Group, a CRO delivering R&D services and production in lyophilisation to the pharma/biopharma and other industries. 
She has also held senior roles at SAFC Pharma and Pharmorphix of Sigma Aldrich in Cambridge and at Cancer Research UK in London.

    Laura holds both a Ph.D. and an M.Eng Honours Degree in Biochemical Engineering from University College London, University of London and received awards from CellTech, IChemE for work in biochemical engineering, as well as being Dean Listed by the UCL Engineering Faculty.